

Supporting Information

$\it trans$ -Hydrogenation: Application to a Concise and Scalable Synthesis of Brefeldin A^{**}

Michael Fuchs and Alois Fürstner*

anie_201411618_sm_miscellaneous_information.pdf

TOTAL SYNTHESES OF BREFELDIN A

Autor (*)	Year ^[a]	Ref.	shown substrate ^[b]	"real" substrate ^[c]	macrocycl	macrocyclization		Amount ^[e]	Comments ^[f]
					method	yield (%)	-		
Corey	1976	1	COOEt	cyclopentadiene	lactonization	nr	≈ 22	nr	racemic
Bartlett	1978	2	о=СООН	EtOOC COOEt	lactonization	37	≈ 17	1 mg	racemic Birch-reduction ($\Delta^{10,11}$)
Kitahara, Mori	1979	3	>0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	mannitol & glutamic acid	lactonization	42	≈ 31	2.9 mg	Birch-reduction ($\Delta^{10,11}$)
Greene	1980	4,5		cyclopentadiene	lactonization	70 ^[h]	≈18	16.1 mg	
Winterfeldt	1980	6		cyclopentadiene (?)	lactonization	nr	> 15	nr	racemic
Yamaguchi	1981	7	O—COOH	EtOOC COOEt	lactonization	94 ^[h]	≈ 21	nr	racemic
Gais	1984	8	MeOOC O	COOMe	lactonization	74	≈ 24	nr	Birch-reduction ($\Delta^{10,11}$)
Corey	1990	9	H.,,,,,	cyclopentadiene	lactonization ^[g]	nr	≈ 17	nr	
Takano	1990	10	CI		lactonization	83	≈ 25	nr	Birch-reduction ($\Delta^{10,11}$)
Taber	1991	11	OMe		lactonization	21 ^[i]	≈ 23	1.1 mg	
Nokami	1991	12	HO,,,	cyclopentadiene	lactonization	80	≈ 16	nr	
Solladié	1993	13	O=OTPS OBn	bis-(+)-menthyl fumarate	lactonization	50	≈ 38	4.2 mg	
Kajiwara	1994	14	OH O CI OMe	Turriur acc	lactonization	24 ^[i]	≈ 22	nr	Birch-reduction ($\Delta^{10,11}$)

			ОН						
Roberts	1994	15		cyclopentadiene	lactonization	80	≈ 14	5.2 mg	
Haynes	1997	16	O=\(\)_'',\(\)OCMe_3	cyclopentadiene (?)	lactonization	78	> 16	5.9 mg	
Suh	1998	17	OMe N	malic acid	lactonization	51	≈ 18	2.2 mg	
Romo	2002	18	OH O		HWE @ $\Delta^{2,3}$	41	≈ 15	nr	
			OEt		nitrile-oxide	78 ^[h]			
Kim	2002	19	EtO	ethyl lactate	cycloadd.	76	≈ 23	14.8 mg	
Trost	2002	20		furan	lactonization	61	≈ 18	8.1 mg	trans-reduction by hydrosilylation/desilylation $(\Delta^{2,3})$
Wu	2004	21	BocO		lactonization	81	≈ 16	14 mg	silylation, desilylation (\(\triangle \)
		22	SO ₂ Ph	T-0^_1				•	
Suh	2006	22		TsO' \\O	HWE @ $\Delta^{2,3}$	59	≈ 15	nr	
Tae	2009	23	O, OH	OH	RCM @ $\Delta^{10,11}$	81	≈ 14	4.8 mg	

- [a] first appearance; "variants" are considered under one entry if the overall strategy is unchanged
- [b] substrate with which the sequence described in the cited reference starts
- [c] compound from which the substrate shown in the publication has been made according to the cited literature; not in all cases this may be the actual point of departure; (?) indicates cases, where the real starting material is not clear (best guess by the present authors)
- [d] the step count is not necessarily unambiguous
- [e] amount of brefeldin A shown in the Experimental Part of the publication
- [f] strategic elements related to the present synthesis are indicated in blue
- [g] also reports an attempted but unsuccessful macrocyclization via intramolecular 1,4-addition
- [h] yield of a mixture of diastereomers
- [i] yield over more than one step; the yield of the macrocyclization itself is not specified

nr = not reported; HWE = Horner-Wadsworth-Emmons olefination; RCM = ring closing alkene metathesis

FORMAL TOTAL SYNTHESES OF BREFELDIN A

Autor (*)	Year ^[a]	Ref.	shown Substrate ^[b]	"real" substrate ^[c]	Steps (Σ) ^[d]	Comments
Ohrui	1980	24	O O O O O O O O O O O O O O O O O O O	glucose	>> 20	intercepts ref. 7
Winterfeldt	1981	25	OAc	cyclopentadiene (?)		racemic, HWE @ $\Delta^{2,3}$ (yield not reported) intercepts ref. 6
Greene	1982	5	OMe	ОН	>> 13	racemic; intercepts ref. 1
Isoe	1985	26	момо	0=	≈ 18	intercepts ref. 2
Sakai	1985	27	HO	но	>> 20	intercepts ref. 3
Trost	1986	28	MeOOC	mannitol	≈ 20	intercepts ref. 1
Nakai	1995	29	TBSO" O		≈ 20	no route established at the time is intercepted
Greene	1995	30	Ph (Co) ₂ (CO) ₆	OH Ph	≈ 18	intercepts ref. 5
Kobayashi	1996	31	HO,,,	cyclopentadiene (?)	≈ 15	intercepts ref. 2

Mioskowski	1999	32	BnO Br	propargyl alcohol (?)	> 20	intercepts ref. 8a
Kim	2002	33	но	tri-O-acetyl-D-glucal	≈ 27	intramol. nitrile-oxide cycloadd. (84%) Birch-reduction ($\Delta^{10,11}$) intercepts ref. 19
Kim	2002	33	но	tri-O-acetyl-D-glucal	≈ 22	RCM @ $\Delta^{10,11}$ (42%, E:Z = 2.2:1); intercepts ref. 19
Helmchen	2006	34	OTBDPS	2-buten-1,4-diol	≈ 19	intercepts ref. 11
Zercher	2007	35	EtO OH	malic acid	≈ 17	RCM @ $\Delta^{10,11}$ (64%, E:Z = 3.5:1) & ring expansion intercepts ref. 19
other		36				

- [a] first appearance; "variants" are considered under one entry if the overall strategy is unchanged
- [b] substrate with which the sequence described in the cited reference starts
- [c] compound from which the substrate shown in the publication has been made according to the cited literature; not in all cases this may be the actual point of departure; (?) indicates cases, where the real starting material is not clear (best guess by the present authors)
- [d] projected number of steps towards the final product if the synthesis were completed according to the intercepted route; the step count is not necessarily unambiguous

TOTAL AND FORMAL SYNTHESES OF BREFELDIN C

Autor (*)	Year ^[a]	Ref.	shown Substrate ^[b]	"real" substrate ^[c]	Macrocyclization (yield %)	Steps (Σ) ^[d]	Amount ^[e]	Comments ^[f]
Schreiber	1988	37			NHK (60%)	≈ 16	≈ 5 mg	
Takano	1989	38	ООН		lactonization (85%)	≈ 22	nr	Birch-reduction ($\Delta^{10,11}$)
Guingant	2005	39		СООН	lactonization (79%)	≈ 18	50 mg	
Tsunoda	2011	40	ОН	ОН	lactonization (89%)	≈ 23	nr	

- [a] first appearance; "variants" are considered under one entry if the overall strategy is unchanged
- [b] substrate with which the sequence described in the cited reference starts
- [c] compound from which the substrate shown in the publication has been made according to the cited literature; not in all cases this may be the actual point of departure; (?) indicates cases, where the real starting material is not clear (best guess by the present authors)
- [d] the step count is not necessarily unambiguous
- [e] amount of brefeldin A shown in the Experimental Part
- [f] strategic elements related to the present synthesis are indicated in blue

nr = not reported; NHK = Nozaki-Hiyama-Kishi reaction

A SELECTION OF SIGNIFICANT ANALOGUES

Autor (*)	Year	Ref.	Structure ^[a]	Amount
Hori	1997/2000	41	various derivatives	prepared by derivatization of BFA
Cushman	1998	42	various prodrugs	prepared by derivatization of BFA
Helmchen	2006	34	HO HO 15	nr
Helmchen	2006	34	7 H OH O	nr
Wu	2008	43	HO::: 0 HO::: 0 HO::: 0	14 mg
Helmchen	2008/2011	44,45	H OH N	14.3 mg (for total synthesis) 125 mg (via partial synthesis)
Guingant	2010	39a	HO 4 0H 0 0 15	58 mg
Helmchen	2011	45	HO	10.8 mg

Helmchen	2011	45	H ₂ N···· T H OH OH OH OH OH OH OH OH	23 mg (via partial synthesis)
Helmchen	2013	46	HOW TO HO	R = Et, 43 mg R = CF ₃ , 18.8 mg R = vinyl, 78.6 mg Ar = Ph, 42 mg Ar =1-naphthyl, 25.8 mg Ar = 6-quinolinyl, 21.4 mg Ar = 4-dimethylaminophenyl, 18.7 mg Ar = 4-trifluoromethylphenyl, 37.4 mg, Ar = 4-fluoromethyl, 33.4 mg (all via partial synthesis)

[a] modified site and/or modification relative to the natural product shown in red

a) E. J. Corey, R. H. Wollenberg, *Tetrahedron Lett*. **1976**, 4705-4708; b) for a modification, see: E. J. Corey, R. H. Wollenberg, D. R. Williams, *Tetrahedron Lett*. **1977**, 2243-2246.

P. A. Bartlett, F. R. Green, *J. Am. Chem. Soc.* **1978**, *100*, 4858-4865.

- a) T. Kitahara, K. Mori, M. Matsui, *Tetrahedron Lett.* **1979**, *20*, 3021-3024; b) T. Kitahara, K. Mori, *Tetrahedron* **1984**, *40*, 2935-2944.
- ⁴ A. E. Greene, C. Le Drian, P. Crabbé, *J. Am. Chem. Soc.* **1980**, *102*, 7583-7584.
- ⁵ C. Le Drian, A. E. Greene, *J. Am. Chem. Soc.* **1982**, *104*, 5473-5483.
- a) Y. Köksal, P. Raddatz, E. Winterfeldt, Angew. Chem. 1980, 92, 486-487; Angew. Chem. Int. Ed. Engl. 1980, 19, 472-473; b) Y. Köksal, P. Raddatz, E. Winterfeldt, Liebigs Ann. Chem. 1984, 450-461.
- M. Honda, K. Hirata, H. Sueoka, T. Katsuki, M. Yamaguchi, *Tetrahedron Lett.* **1981**, 22, 2679-2682.
- a) H.-J. Gais, T. Lied, Angew. Chem. 1984, 96, 143-145; Angew. Chem. Int. Ed. Engl. 1984, 23, 145-146;
 b) H.-J. Gais, K. L. Lukas, Angew. Chem. 1984, 96, 140-141; Angew. Chem. Int. Ed. Engl. 1984, 23, 142-143.
- E. J. Corey, P. Carpino, Tetrahedron Lett. 1990, 31, 7555-7558.
- S. Hatakeyama, K. Sugawara, M. Kawamura, S. Takano, *Synlett* **1990**, 691-693.
- D. F. Taber, L. J. Silverberg, E. D. Robinson, J. Am. Chem. Soc. **1991**, 113, 6639-6645.
- ¹² J. Nokami, M. Ohkura, Y. Dan-Oh, Y. Sakamoto, *Tetrahedron Lett.* **1991**, *32*, 2409-2412.
- ¹³ G. Solladié, O. Lohse, *J. Org. Chem.* **1993**, *58*, 4555-4563.
- ¹⁴ H. Miyaoka, M. Kajiwara, *J. Chem. Soc. Chem. Commun.* **1994**, 483-484.
- a) G. Casy, G. Gorins, R. McCague, H. F. Olivo, S. M. Roberts, J. Chem. Soc. Chem. Commun.
 1994, 1085-1086; b) A. J. Carnell, G. Casy, G. Gorins, A. Kompany-Saeid, R. McCague, H. F. Olivo, S. M. Roberts, A. J. Willetts, J. Chem. Soc. Perkin Trans. I 1994, 3431-3439.
- ¹⁶ R. K. Haynes, W. W.-L Lam, L.-L. Yeung, I. D. Williams, A. C. Ridley, S. M. Starling, S. C. Vonwiller, T. W. Hambley, P. Lelandais, *J. Org. Chem.* **1997**, *62*, 4552-4553.
- a) Y.-G. Suh, J.-K. Jung, B.-C. Suh, Y.-C. Lee, S.-A. Kim, *Tetrahedron Lett.* 1998, 39, 5377-5380; b)
 Y.-G. Suh, J.-K. Jung, S.-Y. Seo, K.-H. Min, D.-Y. Shin, Y.-S. Lee, S.-H. Kim, H.-J. Park, *J. Org. Chem.* 2002, 67, 4127-4137; c) Y.-G. Suh, S.-Y. Seo, J.-K. Jung, O.-H. Park, R.-O. Jeon, *Tetrahedron Lett.* 2001, 42, 1691-1694.
- ¹⁸ Y. Wang, D. Romo, *Org. Lett.* **2002**, *4*, 3231-3234.
- D. Kim, J. Lee, P. J. Shim, J. I. Lim, H. Jo, S. Kim, *J. Org. Chem.* **2002**, *67*, 764-771.
- ²⁰ a) B. M. Trost, M. L. Crawley, *J. Am. Chem. Soc.* **2002**, *124*, 9328-9329; b) B. M. Trost, M. L. Crawley, *Chem. Eur. J.* **2004**, *10*, 2237-2252.
- ²¹ a) Y. Wu, J. Gao, *Org. Lett.* **2008**, *10*, 1533-1536; for a variant, see: b) Y. Wu, X. Shen, Y.-Q. Yang, Q. Hu, J.-H. Huang, *J. Org. Chem.* **2004**, *69*, 3857-3865; c) Y. Wu, X. Shen, Y.-Q. Yang, Q. Hu, J.-H. Huang, *Tetrahedron Lett.* **2004**, *45*, 199-202.
- ²² S.-Y. Seo, J.-K. Jung, S.-M. Paek, Y.-S. Lee, S.-H. Kim, Y.-G. Suh, *Tetrahedron Lett.* **2006**, *47*, 6527-6539.
- ²³ M.-Y. Kim, H. Kim, J. Tae, *Synlett* **2009**, 1303-1306.
- ²⁴ H. Ohrui, H. Kuzuhara, *Agric. Biol. Chem.* **1980**, *44*, 907-912.
- ²⁵ P. Raddatz, E. Winterfeldt, *Angew. Chem.* **1981**, *93*, 281-282; *Angew. Chem. Int. Ed. Engl.* **1981**, *20*, 286-287.
- ²⁶ K. Nakatani, S. Isoe, *Tetrahedron Lett.* **1985**, *26*, 2209-2212.
- ²⁷ K. Ueno, H. Suemune, S. Saeki, K. Sakai, *Chem. Pharm. Bull.* **1985**, *33*, 4021-4025.

-

- ²⁸ B. M. Trost, J. Lynch, P. Renaut, D. H. Steinman, *J. Am. Chem. Soc.* **1986**, *108*, 284-291.
- ²⁹ K. Tomooka, K. Ishikawa, T. Nakai, *Synlett* **1995**, 901-902.
- ³⁰ V. Bernardes, N. Kann, A. Riera, A. Moyano, M. A. Pericas, A. E. Greene, *J. Org. Chem.* **1995**, *60*, 6670-6671.
- Y. Kobayashi, K. Watatani, Y. Kikori, R. Mizojiri, *Tetrahedron Lett.* **1996**, *37*, 6125-6128.
- P. Ducray, B. Rousseau, C. Mioskowski, J. Org. Chem. **1999**, *64*, 3800-3801.
- D. Kim, J. Lee, P. J. Shim, J. I. Lim, T. Doi, S. Kim, *J. Org. Chem.* **2002**, *67*, 772-781.
- T. Hübscher, G. Helmchen, *Synlett* **2006**, 1323-1326.
- ³⁵ W. Lin, C. K. Zercher, *J. Org. Chem.* **2007**, *72*, 4390-4395.
- For other studies towards the brefeldins, see: a) D. B. Ramachary, Y. V. Reddy, J. Org. Chem.
 2010, 75, 74-85; b) D. P. Curran, D. Scholz, Monatsh. Chem. 1977, 108, 1401-1411; c) T. Livinghouse, R. V. Stevens, J. Chem. Soc. Chem. Commun. 1978, 754-756; d) R. Baker, R. B. Keen, M. D. Morris, R. W. Turner, J. Chem. Soc. Chem. Commun. 1984, 987-988; e) K. Nakamura, T. Kitayama, Y. Inoue, A. Ohno, Bull. Chem. Soc. Jpn. 1990, 63, 91-96.
- ³⁷ S. L. Schreiber, H. V. Meyers, *J. Am. Chem. Soc.* **1988**, *110*, 5198-5200.
- S. Hatakeyama, K. Osanai, H. Numata, S. Takano, Tetrahedron Lett. 1989, 30, 4845-4848.
- a) S. Archambaud, F. Legrand, K. Aphecetche-Julienne, S. Collet, A. Guingant, M. Evain, Eur. J. Org. Chem. 2010, 1364-1380; b) S. Archambaud, K. Aphecetche-Julienne, A. Guingant, Synlett 2005, 139-143; c) F. Legrand, S. Archambaud, S. Collet, K. Aphecetche-Julienne, A. Guingant, M. Evain, Synlett 2008, 389-393.
- M. Inai, T. Nishii, S. Mukoujima, T. Esumi, H. Kaku, K. Tominaga, H. Abe, M. Horikawa, T. Tsunoda, *Synlett* **2011**, 1459-1461.
- a) J.-W. Zhu, H. Nagasawa, F. Nagura, S. B. Mohamad, Y. Uto, K. Ohkura, H. Hori, *Bioorg. Med. Chem.* **2000**, *8*, 455-463; b) J.-W. Zhu, H. Hori, H. Nojiri, T. Tsukuda, Z. Taira, *Bioorg. Med. Chem. Lett.* **1997**, *7*, 139-144.
- ⁴² A. B. Argade, R. Devraj, J. A. Vroman, R. D. Haugwitz, M. Hollingshead, M. Cushman, *J. Med. Chem.* **1998**, *41*, 3337-3346.
- ⁴³ J. Gao, Y.-X. Huang, Y. Wu, *Tetrahedron* **2008**, *64*, 11105-11109.
- ⁴⁴ S. Förster, G. Helmchen, *Synlett* **2008**, 831-836.
- S. Förster, E. Persch, O. Tverskoy, F. Rominger, G. Helmchen, C. Klein, B. Gönen, B. Brügger, *Eur. J. Org. Chem.* **2011**, 878-891.
- K. Seehafer, F. Rominger, G. Helmchen, M. Langhans, D. G. Robinson, B. Özata, B. Brügger, J. R.
 P. M. Strating, F. J. M. van Kuppeveld, C. D. Klein, J. Med. Chem. 2013, 56, 5872-5884.




Figure S-1. Structure of compound **8** in the solid state; anisotropic displacement parameters are drawn at the 50% probability level, hydrogen atoms are omitted for clarity; brefeldin numbering scheme **(CCDC-1036054)**

X-ray Crystal Structure Analysis of Compound 8: $C_7 H_{10} O_3$, $M_r = 142.15 \text{ g} \cdot \text{mol}^{-1}$, colorless plate, crystal size $0.32 \times 0.19 \times 0.12 \text{ mm}$, monoclinic, space group $P2_1$, a = 5.3098(4) Å, b = 10.2790(7) Å, c = 12.3060(9) Å, $\beta = 97.493(4)^\circ$, $V = 665.92(8) \text{ Å}^3$, T = 100 K, Z = 4, $D_{calc} = 1.418 \text{ g} \cdot \text{cm}^3$, $\lambda = 1.54178 \text{ Å}$, $\mu(Cu-K_\alpha) = 0.930 \text{ mm}^{-1}$, Empirical absorption correction ($T_{\text{min}} = 0.77$, $T_{\text{max}} = 0.90$), Bruker AXS X8 Proteum diffractometer, $3.623 < \theta < 66.290^\circ$, 14753 measured reflections, 2300 independent reflections, 2182 reflections with $I > 2\sigma(I)$, Structure solved by direct methods and refined by full-matrix least-squares against F^2 to $R_1 = 0.030 [I > 2\sigma(I)]$, $wR_2 = 0.078$, 183 parameters, H atoms riding, absolute structure parameter = 0.0(2), S = 1.040, residual electron density $0.2 / -0.2 \text{ e} \text{ Å}^{-3}$.




Figure S-2. Structure of adduct **12** in the solid state; anisotropic displacement parameters are drawn at the 50% probability level, hydrogen atoms are omitted for clarity (**CCDC-1036055**)

X-ray Crystal Structure Analysis of Compound 12: $C_8 H_{10} Cl_2 O_2$, $M_r = 209.06 \text{ g} \cdot \text{mol}^{-1}$, colorless plate, crystal size $0.21 \times 0.20 \times 0.17$ mm, orthorhombic, space group $P2_12_12_1$, a = 8.0685(5) Å, b = 9.3727(5) Å, c = 11.7206(7) Å, V = 886.35(9) Å³, T = 100 K, Z = 4, $D_{calc} = 1.567 \text{ g} \cdot \text{cm}^3$, $\lambda = 1.54178$ Å, $\mu(Cu-K_\alpha) = 6.234 \text{ mm}^{-1}$, Empirical absorption correction ($T_{min} = 0.34$, $T_{max} = 0.49$), Bruker AXS X8 Proteum

diffractometer, $6.045 < \theta < 67.622^{\circ}$, 40841 measured reflections, 1594 independent reflections, 1587 reflections with $I > 2\sigma(I)$, Structure solved by direct methods and refined by full-matrix least-squares against F^2 to $R_1 = 0.025$ [$I > 2\sigma(I)$], $wR_2 = 0.061$, 109 parameters, absolute structure parameter = 0.012(5), H atoms riding, S = 1.098, residual electron density 0.1 / -0.3 e Å⁻³.




Figure S-3. Structure of cycloalkyne **20** in the solid state in two different orientations; anisotropic displacement parameters are drawn at the 50% probability level; except for H3 shown in the top projection, all hydrogen atoms are omitted for clarity (**CCDC-1036056**)

X-ray Crystal Structure Analysis of Compound 20: C_{16} H₂₂ O₄, $M_r = 278.33$ g · mol⁻¹, colorless plate, crystal size 0.21 x 0.11 x 0.07 mm, orthorhombic, space group $P2_12_12_1$, a = 7.4004(2) Å, b = 10.6316(3) Å, c = 18.5415(5) Å, V = 1458.81(7) Å³, T = 100 K, Z = 4, $D_{calc} = 1.267$ g·cm³, $\lambda = 1.54178$ Å, $\mu(Cu-K_{\alpha}) = 0.732$ mm⁻¹, Semi-empirical absorption correction ($T_{min} = 0.87$, $T_{max} = 0.95$), Bruker AXS X8 Proteum diffractometer, 4.770 < θ < 67.815°, 65420 measured reflections, 2618 independent reflections, 2541 reflections with $I > 2\sigma(I)$, Structure solved by direct methods and refined by full-matrix least-squares against F^2 to $R_1 = 0.032$ [$I > 2\sigma(I)$], $wR_2 = 0.078$, 190 parameters, absolute structure parameter = 0.07(6), H atoms riding, S = 1.108, residual electron density 0.1 / -0.2 e Å⁻³.




Figure S-4. Structure of brefeldin A (1) in the solid state; anisotropic displacement parameters are drawn at the 50% probability level, hydrogen atoms are omitted for clarity (**CCDC- 1036057**)¹

X-ray Crystal Structure Analysis of 9022: $C_{16} H_{24} O_4$, $M_r = 280.35 \text{ g} \cdot \text{mol}^{-1}$, colorless plate, crystal size 0.187 x 0.172 x 0.040 mm, orthorhombic, space group $P2_12_12_1$, a = 7.3601(3) Å, b = 10.8657(5) Å, c = 18.7697(9) Å, V = 1501.06(12) Å³, T = 100 K, Z = 4, $D_{calc} = 1.241$ g · cm³, $\lambda = 1.54178$ Å, $\mu(Cu-K_\alpha) = 0.712 \text{ mm}^{-1}$, Empirical absorption correction ($T_{min} = 0.90$, $T_{max} = 0.97$), Bruker AXS X8 Proteum diffractometer, $4.702 < \theta < 67.536^\circ$, 62428 measured reflections, 2704 independent reflections, 2644 reflections with $I > 2\sigma(I)$, Structure solved by direct methods and refined by full-matrix least-squares against F^2 to $R_1 = 0.030$ [$I > 2\sigma(I)$], $wR_2 = 0.072$, 198 parameters, absolute structure parameter = 0.00(6), H atoms riding, S = 1.096, residual electron density 0.1 / -0.2 e Å⁻³.

CCDC-1036054 (**8**), CCDC-1036055 (**12**), CCDC-1036056 (**20**) and CCDC-1036057 (**1**) contain the supporting crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.

-

For a previous report on the X-ray structure of brefeldin A, see: H. P. Weber, D. Hauser, H. P. Sigg, *Helv. Chim. Acta* **1971**, *54*, 2763-2766.

General. Unless stated otherwise, all reactions were carried out under Ar in flame-dried glassware. The solvents were purified by distillation over the indicated drying agents and were transferred under Ar: THF, Et₂O (Mg/anthracene), CH₂Cl₂, hexane, toluene (Na/K), dioxane, DMF, MeCN, NEt₃ and pyridine were dried by an adsorbtion solvent purification system based on molecular sieves. Thin layer chromatography (TLC): Macherey-Nagel precoated plates (POLYGRAM® SIL/UV254); Flash chromatography: Merck silica gel 60 (40-63 µm) with predistilled or HPLC grade solvents. NMR: Spectra were recorded on Bruker DPX 300, AV400, AV500 or AVIII 600 spectrometer in the solvents indicated; chemical shifts (δ) are given in ppm relative to TMS, coupling constants (J) in Hz. The solvent signals were used as references and the chemical shifts converted to the TMS scale (CDCl₃: δ_C \equiv 77.16 ppm; residual CHCl₃ in CDCl₃: $\delta_{\rm H}$ \equiv 7.26 ppm; [D₄]-MeOH: $\delta_{\rm C}$ \equiv 49.00 ppm; residual CHD₂OD in [D₄]-methanol: $\delta_H \equiv 3.31$ ppm; [D₆]-DMSO: $\delta_C \equiv 39.52$ ppm; residual [D₅]-DMSO: $\delta_H \equiv 2.50$ ppm); IR: Spectrum One (Perkin-Elmer) spectrometer, wavenumbers (ũ) in cm⁻¹; MS (EI): Finnigan MAT 8200 (70 eV), ESI-MS: ESQ 3000 (Bruker), accurate mass determinations: Bruker APEX III FT-MS (7 T magnet) or Mat 95 (Finnigan). Optical rotations (α_D^{20}) were measured with a Perkin-Elmer Model 343 polarimeter. Unless stated otherwise, all commercially available compounds (Alfa Aesar, Aldrich, Fluka, Lancaster) were used as received. Complex 26^[1] and [Cp*Ru(MeCN)₃]PF₆^[2] were prepared according to literature procedures.

(1*R*,2*S*)-Diethyl cyclohex-4-ene-1,2-dicarboxylate (3). $^{[3]}$ H₂SO₄ (conc., 25 mL, 469 mmol) was added to a solution of *cis*-1,2,3,6-tetrahydrophthalic anhydride (60.0 g, 394 mmol) in MeOH (600 mL) and the resulting mixture was stirred overnight at reflux temperature. The mixture was then concentrated under reduced pressure and the remaining oil diluted with water (100 mL). Solid NaHCO₃ was carefully added until the pH was neutral. The aqueous phase was extracted with *tert*-butyl methyl ether (4 x 100 mL), and the combined organic phases were dried over Na₂SO₄, filtered and concentrated to give product **3** as a clear oil (75.0 g, 96%). 1 H NMR (400 MHz, CDCl₃): δ = 5.65 (s, 2H), 3.67 (s, 6H), 3.02 (t, J = 5.3, 2H), 2.53 (dd, J = 5.3, 16.2 Hz, 2H); 13 C NMR (100 MHz, CDCl₃): δ = 173.8, 125.2, 51.9, 39.8, 25.8; IR (film) \tilde{v} = 3029, 2952, 2848, 1729, 1435, 1200, 1163, 1025, 660; MS (EI): m/z: 198 (0.25), 167 (14), 138 (35), 107 (9), 91 (1), 79 (100), 59 (9); HRMS (ESI): m/z: calc. for C₁₀H₁₄O₄Na: 221.0784 [M+Na]⁺, found: 221.0785.

(1R,6S)-6-(Methoxycarbonyl)cyclohex-3-enecarboxylic acid (4). Diester 3 (74.5 g, 376 mmol) was suspended in phosphate buffer (1340 mL, 100 mM, pH = 7.0). Pig liver esterase (10.9 kU, 728 mg lyophilized powder) and ammonium sulfate (3 M in water, 3.16 mL) were added and the pH was kept constant by addition of NaOH (1 M) via a pH-stat for 2 d. For work up, the pH was adjusted to \approx 10 by the addition of NaOH (1 M) and the obtained slurry was extracted with tert-butyl methyl ether (2 x 500 mL). The aqueous phase was acidified with conc. HCl until a pH 1 was reached, which led to significant precipitation of the enzyme. To facilitate the extraction, tert-butyl methyl ether (500 mL) was added and the mixture was filtered through a pad of Celite, which was carefully washed with water (100 mL) and tert-butyl methyl ether (100 mL). The

phases were separated and the aqueous phase was extracted with *tert*-butyl methyl ether (2 x 500 mL). The combined organic layers of the second extraction step (under acidic conditions) were dried over Na₂SO₄, filtered and concentrated to give compound **4** as a pale yellow oil (65.2 g, 94%). $\left[\alpha\right]_D^{20} = +17.7$ [c = 1.0, EtOH, lit.:^[5] +17.7 (c = 1.0, EtOH)]; ¹H NMR (400 MHz, CDCl₃): δ = 5.67 (s, 2H), 3.69 (s, 3H), 3.10-3.03 (m, 2H), 2.61-2.54 (m, 2H), 2.40-2.33 (m, 2H); ¹³C NMR (100 MHz, CDCl₃): δ = 179.8, 173.8, 125.3, 125.2, 52.1, 39.7, 39.6, 25.9, 25.7; IR (film) \tilde{v} = 3100br, 3031, 2952, 2851, 1731, 1704, 1655, 1436, 1297, 1264, 1203, 1163, 1033, 736, 663; MS (EI): m/z: 184 (1), 166 (8), 153 (11), 138 (24), 124 (27), 107 (7), 97 (4), 79 (100); HRMS (ESI): m/z: calc. for C₉H₁₁O₄Na₂: 229.0447 [M+2Na]⁺, found: 229.0448.

(3aS,7aR)-3a,4,7,7a-Tetrahydroisobenzofuran-1(3H)-one (5).[6] A flame-dried round bottom flask equipped with a droping funnel was charged with LiEt₃BH (1 M in THF, 608 mL, 608 mmol) under argon. The solution was cooled to 0 °C before a solution of compound 4 (28.0 g, 152 mmol) in THF (20 mL) was added over a period of 30 min. Once the addition was complete, the mixture was stirred for 1 h at 0 °C and for 3 h at room temperature. For work up, the mixture was cooled to 0 °C and the reaction was carefully quenched by addition of aq. HCl (6 M, 500 mL). The resulting mixture was stirred overnight before it was extracted with tert-butyl methyl ether (4 x 200 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated. The residue was purified by flash chromatography (SiO₂, pentane/tert-butyl methyl ether, 3/1) to give the title compound as colorless oil, which was dried under high vacuum for 1 h (20.5 g, 98%). $\left[\alpha\right]_{D}^{20} = +49.7$ [c = 1.8, EtOAc, lit.: $^{[6]}$ +82.5 (c = 2.0, EtOAc)]; 1 H NMR (400 MHz, CDCl₃): δ = 5.73 (s, 2H), 4.30 (dd, J = 5.2, 8.8 Hz, 1H), 4.01 (dd, J = 1.9, 8.8 Hz, 1H), 2.83-2.69 (m, 1H), 2.66-2.57 (m, 1H), 2.52-2.48 (m, 1H), 2.44-2.32 (m, 1H), 2.29-2.23 (m, 1H), 1.93-1.87 (m, 1H); 13 C NMR (100 MHz, CDCl₃): δ = 179.2, 125.3, 124.9, 72.8, 37.4, 32.1, 24.8, 22.1; IR (film) \tilde{v} = 3031, 2969, 2905, 2843, 1763, 1480, 1435, 1372, 1197, 1173, 1132, 1040, 944, 663; MS (EI): m/z: 138 (41), 123 (9), 110 (5), 93 (100), 79 (89); HRMS (ESI): m/z: calc. for C₈H₁₀O₂: 138.0681 [M]⁺, found: 138.0681.

2,2'-[(3R,4S)-2-Oxotetrahydrofuran-3,4-diyl]diacetic acid (6). A solution of lactone 5 (200 mg, 1.45 mmol) in acetone (1 mL) and added dropwise over a period of 1 h to a solution of KMnO₄ (699 mg, 4.42 mmol) in water (5 mL) at 0 °C. The brown slurry was stirred for 1 h at 0 °C, warmed to room temperature and stirred overnight. NaHSO₃ was added in order to destroy any remaining KMnO₄. The resulting slurry was filtered through a pad of Celite and the filter cake carefully rinsed with water/THF (1/1, 25 mL). The combined filtrate was acidified to pH 2, saturated with NaCl and extracted with *tert*-butyl methyl ether/THF (2/3, 6 x 40 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure (the bath temperature must not exceed 30 °C). The remaining while solid material was dried under high vacuum and found pure enough for immediate further use (283 mg, 97%).

The reaction was also performed on much larger scale, using KMnO₄ (119.4 g, 0.76 mol) in water (650 mL) and lactone **5** (26.1 g, 189 mmol) in acetone (139 mL) to give analytically pure **6** (27.3 g, 71%) which analyzed as follows: m.p. = 162-164 °C (EtOAc, lit. [6] 144-157 °C); $[\alpha]_D^{20} = -75.3$ [c = 1.0,

MeOH, lit.:^[6] -85.3 (c = 3.29, MeOH)]; ¹H NMR (400 MHz, [D₆]-DMSO): δ = 12.41 (bs, 2H), 4.38 (dd, J = 6.3, 8.9 Hz, 1H), 4.05 (dd, J = 2.2, 8.9 Hz, 1H), 3.20 (dd, J = 7.9, 14.8 Hz, 1H), 2.94 (bs, 1H), 2.48 (m, 2H), 2.35 (dd, J = 4.8, 16.6 Hz, 1H), 2.23 (dd, J = 10.1, 16.5 Hz, 1H); ¹³C NMR (100 MHz, [D₆]-DMSO): δ = 177.5, 172.9, 172.5, 71.0, 38.7, 34.2, 32.5, 30.2; IR (film) \tilde{v} = 2922 (br), 2578 (br), 1752, 1692, 1416, 1385, 1328, 1296, 1222, 1171, 986, 925; MS (EI): m/z: 203 (0.34), 184 (10), 166 (6), 156 (24), 143 (49), 125 (41), 112 (100), 97 (47), 85 (36), 70 (40), 67 (42), 55 (64); HRMS (ESI): m/z: calc. for C₈H₁₀O₆Na: 225.0370 [M+Na]⁺, found: 225.0370.

(3aS,6aR)-Tetrahydro-1*H*-cyclopenta[c]furan-1,5(3*H*)-dione (7).^[7] Diacid 6 (998 mg, 4.94 mmol) was suspended in Ac₂O (10 mL, 10.8 g, 106 mmol) and the mixture stirred at 130 °C (bath temperature) for 1 h. After cooling to room temperature, the mixture was diluted with THF (15 mL) before K₂CO₃ (667 mg, 4.83 mmol) was added. The resulting mixture was stirred at 60 °C (bath temperature) overnight. After cooling to 0 °C, the reaction was quenched with MeOH (10 mL) and the mixture stirred for 30 min at 0 °C. Sat. aq. NH₄Cl (20 mL) and CH₂Cl₂ (20 mL) were added and stirring continued for 20 min at 0 °C. Phase separation followed by extraction of the aqueous layer with CH₂Cl₂ (3 x 25 mL) gave a combined organic phase, which was dried over Na₂SO₄, filtered and concentrated. The crude product was purified by flash chromatography (SiO₂, hexane/EtOAc, 1/1) to give the title compound as a pale yellow solid (504 mg, 73%).

The reaction was also performed on larger scale, using Ac₂O (124 mL, 134 g, 1.31 mol), diacid **6** (10.0 g, 49.5 mmol), K₂CO₃ (6.84 g, 49.5 mmol) and THF (370 mL) to give analytically pure **7** (3.86 g, 56%) which analyzed as follows: m.p. = 81-82 °C (EtOAc, lit.:^[4a] 84 °C for *ent-***6**); $\left[\alpha\right]_D^{20}$ = +80.6 [c = 1.1, CH₂Cl₂, lit.:^[4a] -67.8 (c = 2.59, CH₂Cl₂, for *ent-***6**); ¹H NMR (400 MHz, CDCl₃): δ = 4.53 (dd, J = 5.9, 9.6 Hz, 1H), 4.25 (d, J = 11.5, 1H), 3.40-3.11 (m, 2H), 2.79-2.51 (m, 3H), 2.21 (dd, J = 8.3, 19.1 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 214.0, 178.1, 71.8, 42.2, 40.8, 39.3, 36.3; IR (film) \tilde{v} = 2975, 2920, 1765, 1732, 1403, 1371, 1308, 1185, 1173, 1097, 1033, 975; MS (EI): m/z: 140 (72), 122 (4), 112 (15), 99 (64), 95 (23), 81 (35), 67 (73), 54 (100); HRMS (ESI): m/z: calc. for C₇H₈O₃: 140.0473 [M]⁺, found: 140.0474.

(3aS,5R,6aR)-5-Hydroxyhexahydro-1*H*-cyclopenta[c]furan-1-one (8). [4a] NaOAc (7.04 g, 85.8 mmol) and Pt/C (10 wt-%, 781 mg, 1.4 mol-%) were added to a solution of keto-lactone **7** (4.01 g, 28.6 mmol) in EtOAc (120 mL) and the mixture was stirred under an atmosphere of hydrogen (1 atm) for 1.5 d. The suspension was filtered through a pad of silica which was carefully rinsed with EtOAc (2 x 20 mL). The combined filtrates were evaporated under reduced pressure to give the title compound as pale yellow solid (4.04 g, 99%): m.p. = 64-65°C (EtOAc, lit.: [8] 69-70°C); α [α] α = -71.0 [c = 2.0, CH₂Cl₂, lit.: [8] -59.5 (c = 1.73, CH₂Cl₂)]; α 1H NMR (400 MHz, CDCl₃): α = 4.53 (t, α = 8.7, 1H), 4.44 (t, α = 3.8, 1H), 4.21 (dd, α = 3.1, 9.2 Hz, 1H), 3.16-2.89 (m, 2H), 2.28-2.23 (m, 1H), 2.07-1.90 (m, 2H), 1.88-1.76 (m, 2H); α NMR (100 MHz, CDCl₃): α = 181.5, 74.7, 73.6, 43.3, 42.3, 40.4, 36.9; IR (film) α = 3451br, 2939, 1744, 1383, 1265, 1192, 1140, 1105, 1008, 977, 734, 701; MS (EI): α = 142 (43), 124 (47), 113 (32), 96 (20), 83 (55), 69 (62), 55 (100); HRMS (ESI): α = calc. for

 $C_7H_{10}O_3$: 142.0630 [M] $^+$, found: 142.0628. Single crystals suitable for X-ray diffraction were obtained from a solution in EtOAc upon slow evaporation of the solvent.

(3aS,5R,6aR)-5-[(tert-Butyldimethylsilyl)oxy]hexahydro-1H-cyclopenta[c]furan-1-one (9). TBSOTf (9.78 mL, 11.3 g, 42.6 mmol) was added dropwise at 0 °C to a solution of 2,6-lutidine (6.6 mL, 6.09 g, 56.8 mmol) and hydroxylactone **6** (4.04 g, 28.4 mmol) in CH₂Cl₂ (38 mL). After stirring for 1 h at 0 °C, the reaction was quenched by the addition of sat. aq. NaHCO₃ (ca. 10 mL) and the aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic phases were washed with aq. CuSO₄ (1 M, 5 x 15 mL) and brine (10 mL), before they were dried over Na₂SO₄, filtered and concentrated. The residue was dried under high vacuum to give pure **9** as pale yellow solid (7.12 g, 98%). m.p. = 48-49 °C (EtOAc); $\left[\alpha\right]_D^{20} = -20.3$ (c = 1.6, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ = 4.51 (t, J = 8.7, 1H), 4.34-4.32 (m, 1H), 4.17-4.14 (m, 1H), 3.04-2.99 (m, 2H), 2.20 (d, J = 13.5 Hz, 1H), 1.94-1.85 (m, 2H), 1.75 (d, J = 13.6 Hz, 1H), 0.85 (s, 9H), 0.04 (s, 6H); ¹³C NMR (100 MHz, CDCl₃): δ = 181.1, 74.9, 74.2, 43.7, 43.5, 40.7, 37.2, 26.0, 18.2, -4.62, -4.65; IR (film) \tilde{v} = 2958, 2928, 2856, 1751, 1377, 1255, 1195, 1045, 1023, 908, 833, 773; MS (EI): m/z: 241 (3), 199 (93), 169 (12), 141 (14), 125 (4), 105 (7), 89 (6), 75 (100), 59 (7); HRMS (ESI): m/z: calc. for C₁₃H₂₄O₃SiNa:

279.1387 [M+Na]⁺, found: 279.1383.

-4.9.

{(15,2R,4S)-4-[(tert-Butyldimethylsilyl)oxy]-2-(prop-1-yn-1-yl)cyclopentyl]methanol (11). A flame dried 2-neck round bottom flask, equipped with a reflux condenser and a dropping funnel, was charged with PPh₃ (43.4 g, 165 mmol). THF (450 mL) and the lactone **9** (5.31 g, 20.7 mmol) were added and the mixture was stirred at reflux temperature (oil-bath temperature ≈ 80 °C). A solution of CCl₄ (50 mL, 79.5 g, 516 mmol) in THF (50 mL) was added dropwise over a period of 3.5 h. Once the addition was complete, stirring was continued at this temperature for 3 h, before the mixture was cooled and the reaction quenched with water (10 mL). The mixture was extracted with tert-butyl methyl ether (3 x 200 mL), the combined organic phases were washed with sat. aq. NaHCO₃ (100 mL) and brine (50 mL), before they were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography (SiO₂, hexane/EtOAc, 50/1) to give the dichloro-olefin **10** (containing minor PPh₃ impurities) which was immediately used for the subsequent reaction. Characteristic data of **10**: 1 H

NMR (400 MHz, CDCl₃): δ = 4.45 (t, J = 8.6, 1H), 4.32-4.26 (m, 2H), 3.39 (dt, J = 4.6, 9.3 Hz, 1H), 3.21 (s, 1H), 3.02-2.92 (m, 1H), 2.06-2.02 (m, 2H), 1.94-1.88 (m, 1H), 1.72-1.66 (m, 1H), 0.87 (s, 9H), 0.04 (s, 6H); 13 C NMR (100 MHz, CDCl₃): δ = 159.5, 79.5, 77.4, 74.5, 46.0, 41.4, 41.4, 40.6, 25.8, 18.0, -4.7,

A flame-dried Schlenk tube was charged with $Fe(acac)_3$ (896 mg, 2.54 mmol), ortho-phenylene-diamine (548 mg, 5.07 mmol), Et_2O (120 mL) and the crude dichloro-olefin **10** from the previous reaction. The solution was cooled to 0 °C before MeLi (1.6 M in Et_2O , 39.6 mL, 63.4 mmol) was slowly added. The mixture was stirred for 10 min at 0 °C and for 2 h at room temperature. For work up, the mixture was cooled to 0 °C before the reaction was carefully quenched with water (20 mL). The aqueous phase was extracted with *tert*-butyl methyl ether (3 x 100 mL) and the combined organic

layers were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography (SiO₂, hexane/EtOAc, 15/1) to give alkyne **11** as an oil (3.02 g, 55%). $\left[\alpha\right]_D^{20} = -2.6$ (c = 2.0, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ = 4.14 (quint, J = 6.5, 1H), 3.82 (dd, J = 7.6, 11.4 Hz, 1H), 3.69-3.64 (m, 1H), 2.80-2.73 (m, 1H), 2.62 (bs, 1H), 2.25-2.16 (m, 2H), 1.98-1.91 (m, 1H), 1.81 (d, J = 2.5 Hz, 3H), 1.73-1.66 (m, 1H), 1.42 (dt, J = 13.1, 6.5 Hz, 1H), 0.87 (s, 9H), 0.04 (s, 6H); ¹³C NMR (100 MHz, CDCl₃): δ = 80.2, 78.5, 72.7, 65.1, 42.8, 42.7, 38.4, 30.2, 26.0, 18.2, 3.7, -4.6, -4.7; IR (film) \tilde{v} = 3414br, 2954, 2929, 2885, 2857, 1472, 1463, 1361, 1256, 1099, 1034, 896, 835, 775, 738; MS (EI): m/z: 268 (0.2), 253 (1), 211 (50), 193 (6), 181 (14), 169 (17), 155 (10), 141 (18), 119 (37), 105 (8), 91 (28), 75 (100); HRMS (ESI): m/z: calc. for C₁₅H₂₈O₂SiNa: 291.1751 [M+Na]⁺, found: 291.1749.

Compound 12. Lactone 9 (8.85 g, 20.7 mmol) was added to a solution of PPh₃ (71.5 g, 273 mmol) in THF (800 mL) and the resulting mixture was stirred at reflux temperature (oil bath temperature ca. 80 °C) when a solution of CCl₄ (83 mL, 132 g, 860 mmol) in THF (50 mL) was added dropwise over a period of 3.5 h. Once the addition was complete, stirring was continued at this temperature for an additional 3 h, before the mixture was allowed to cool and the reaction was quenched with water (10 mL). The mixture was extracted with *tert*-butyl methyl ether (3 x 200 mL), the combined organic phases were washed with sat. aq. NaHCO₃ (100 mL) and brine (50 mL), before they were dried over Na₂SO₄, filtered and concentrated under reduced pressure (*Note*: GC-MS shows that the desired dichloro-olefin 10 was the major component at this point). The crude product was suspended in CH₂Cl₂ (ca. 40 mL) and the solution was ultrasonicated in a laboratory cleaning bath for 1 min. The obtained slurry was purified by flash chromatography (SiO₂, hexane/EtOAc, 20/1 to 4/1) to give product 12 as a white solid (4.59 g, 64%). m.p. = 51-54 °C (hexane/EtOAc 4/1); $\left[\alpha\right]_D^{20} = +38.2$ (c = 0.8, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ = 5.67 (s, 1H), 4.46 (d, J = 0.5, 1H), 4.01 (dd, J = 8.2, 3.7 Hz, 1H), 3.91 (d, J = 8.2, 1H), 2.97-2.96 (m, 1H), 2.70-2.65 (m, 1H),

(15,2R,4S)-4-[(tert-Butyldimethylsilyl)oxy]-2-(prop-1-yn-1-yl)cyclopentane-1-carbaldehyde (S1).

ray diffraction were obtained by sublimation of a sample at 40°C in vacuum (10⁻³ mbar).

2.09-2.00 (m, 2H), 1.72-1.68 (m, 2H); 13 C NMR (100 MHz, CDCl₃): δ = 112.5, 76.6, 74.0, 71.8, 48.5, 39.5, 38.4, 37.8; IR (film) \tilde{v} = 2999, 2973, 2957, 2883, 1437, 1310, 1214, 1140, 1056, 998, 920, 760, 730; MS (EI): m/z: 208 (4), 172 (16), 164 (16), 137 (100), 125 (22), 107 (25), 97 (24), 80 (100), 67 (94); HRMS (ESI): m/z: calc. for $C_8H_{10}O_2Cl_2Na$: 230.9950 [M+Na]⁺, found: 230.9951. Crystals suitable for X-

Pyridine (5.80 mL, 71.7 mmol) and Dess-Martin-periodinane (5.63 g, 13.3 mmol) were successively added to a solution of alcohol **11** (2.38 g, 8.8 mmol) in CH₂Cl₂ (46 mL). The mixture was stirred for 3 h at room temperature before the reaction was quenched with sat. aq. NaHCO₃ (ca. 10 mL). The mixture was extracted with *tert*-butyl methyl ether (3 x 30 mL), the combined organic layers were washed with aq. CuSO₄ (1 M, 4 x 10 mL) and brine (2 x 5 mL) before they were dried over Na₂SO₄. Evaporation of the solvent followed by purification of the crude product by flash chromatography (SiO₂, hexane/EtOAc, 40/1) yielded the title compound in the form of a colorless oil (2.09 g, 89%). $\left[\alpha\right]_D^{20} = +31.4$ (c = 1.0, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ =

9.92 (d, J = 3.2 Hz, 1H), 4.24 (quint, J = 5.9 Hz, 1H), 3.00 (tdd, J = 11.0, 5.5, 2.5 Hz, 1H), 2.72-2.65 (m, 1H), 2.4 (ddd, J = 13.8, 8.3, 6.0 Hz, 1H), 1.99-1.96 (m, 2H), 1.79-1.72 (m, 1H), 1.78 (d, J = 2.5 Hz, 3H), 0.87 (s, 9H), 0.05 (s, 3H), 0.04 (s, 3H); 13 C NMR (100 MHz, CDCl₃): δ = 204.1, 79.9, 78.3, 72.9, 51.5, 43.2, 36.8, 29.5, 25.9, 18.1, 3.7, -4.65, -4.68; IR (film) \tilde{v} = 2930, 2857,1723, 1472, 1361, 1255, 1115, 896, 775; MS (EI): m/z: 266 (0.12), 251 (0.89), 209 (72), 179 (3), 165 (4), 143 (100), 129 (7), 117 (4), 91 (4), 75 (77); HRMS (ESI): m/z: calc. for $C_{15}H_{26}O_2SiNa$: 289.1594 [M+Na] $^+$, found: 289.1596.

(1R,2R,4S)-4-[(tert-Butyldimethylsilyl)oxy]-2-(prop-1-yn-1-yl)cyclopentane-1-carbaldehyde (13).

K₂CO₃ (2.17 g, 15.7 mmol) was added in one portion to a solution of aldehyde **S1** (2.09 g, 7.84 mmol) in MeOH (200 mL) and the resulting mixture was stirred for 3 h at room temperature. EtOAc (ca. 70 mL) was added, followed by aq. sat. NH₄Cl. The aqueous phase was extracted with EtOAc (2 x 70 mL) and the combined organic layers were washed with brine (5 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The remaining crude material was purified by flash chromatography (SiO₂, hexane/toluene, 2/1) to give the title compound as colorless oil (1.84 g, 88%). $\left[\alpha\right]_D^{20} = -22.4$ (c = 1.0, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ = 9.73 (d, J = 1.8, 1H), 4.19 (quint., J = 5.7 Hz, 1H), 3.07 (qd, J = 9.0, 1.8 Hz, 1H), 2.79 (dddd, J = 11.3, 9.0, 6.7, 2.4 Hz, 1H), 2.28 (ddd, J = 13.6, 8.3, 5.8 Hz, 1H), 1.93 (ddd, J = 13.5, 8.6, 6.4 Hz, 1H), 1.83 (ddd, J = 13.3, 9.2, 4.2 Hz, 1H), 1.78 (d, J = 2.4 Hz, 3H), 1.76-1.69 (m, 1H), 0.88 (s, 9H), 0.04 (s, 3H), 0.04 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 202.3, 80.6, 77.4, 72.2, 57.1, 43.5, 35.9, 29.1, 25.9, 18.2, 3.7, -4.64, -4.66; IR (film) \tilde{v} = 3097, 2929, 2857, 1725, 1331, 1302, 1253, 1112, 835, 773; MS (EI): m/z: 209 (100), 195 (3), 179 (3), 169 (8), 151 (3), 143 (14), 117 (10), 105 (20), 97 (8), 91 (4), 75 (77); HRMS (ESI): m/z: calc. for C₁₅H₂₆O₂SiNa: 289.1594 [M+Na]⁺, found: 289.1594.

1-Bromo-3-pentyne (14). Br₂ (6.65 g, 41.6 mmol) was added dropwise at 0 °C to a solution of PPh₃ Br (11.7 g, 44.6 mmol) in MeCN (62 mL) and Et₂O (114 mL) and the resulting mixture was stirred for 20 min at this temperature. Imidazole (3.0 g, 44.66 mmol) was then added in portions before 3-pentyn-1-ol (2.5 g, 29.7 mmol) was slowly introduced. The slurry was stirred for 30 min at 0 °C and for 2 h at ambient temperature. The reaction was quenched with sat. aq. NaHCO₃ and the aqueous phase extracted with pentane (2 x 100 mL). The combined extracts were dried over Na₂SO₄, filtered and concentrated (450-350 mbar, 30 °C bath temperature). The obtained solution was filtered twice through a large pad of silica, eluting with pentane. Concentration of the pentane fractions (350 mbar, 30 °C bath temperature) gave the title compound as clear oil (4.35 g, quant.). H NMR (400 MHz, CDCl₃): δ = 3.41 (t, *J* = 7.4, 2H), 2.69 (tq, *J* = 2.5, 7.3 Hz, 2H), 1.79 (t, *J* = 2.5 Hz, 3H); 13 C NMR (100 MHz, CDCl₃): δ = 78.1, 76.2, 30.5, 23.5, 3.6; IR (film) \tilde{v} = 2969, 2919, 2855, 1436, 1336, 1271, 1212, 919, 871, 745, 698, 637, 566, 503; MS (EI): m/z: 148 (42), 146 (43), 93 (2), 67 (100), 53, (16), 41 (41); HRMS (EI): m/z: calc. for C₅H₇Br: 145.9732 [M], found: 145.9731.

(R)-6-Octyn-2-ol (S2). [14] Bromide 14 (3.59, 24.4 mmol) was added dropwise to a suspension of activated magnesium [15] (832 mg, 34.2 mmol) at 0 °C. The mixture was stirred for 30 min at 0 °C and for 40 min at room temperature. After cooling to -78 °C (15 min cooling time), CuCN (219 mg, 2.44 mmol) followed by (R)-propylene oxide (1.14 mL, 947 mg, 16.3

mmol) was introduced. The resulting mixture was stirred for 30 min at -78 °C before the cooling bath was removed and stirring was continued for 16 h. For work up, the reaction was quenched at 0°C by the careful addition of sat. aq. NH₄Cl (ca. 30 mL), the obtained slurry was filtered through a pad of Celite to remove the remaining magnesium powder and the filtrate was extracted with *tert*-butyl methyl ether (4 x 50 mL). The combined organic phases were dried over Na₂SO₄, filtered and concentrated, and the residue was subjected to flash chromatography (SiO₂, hexane/*tert*-butyl methyl ether, 4/1) to yield the title compound as a pale yellow oil (1.8 g, 88%). $\left[\alpha\right]_D^{20} = -10.6$ (c = 1.2, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ = 3.83-3.80 (m, 1H), 2.19-2.13 (m, 2H), 1.78 (t, J = 2.5 Hz, 3H), 1.63-1.48 (m, 4H), 1.36 [s(br), 1H], 1.20 (d, J = 6.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 79.1, 76.0, 67.9, 38.6, 25.4, 23.7, 18.9, 3.6; IR (film) \tilde{v} = 3351br, 2965, 2920, 2863, 1455, 1435, 1373, 1331, 1182, 1127, 1084, 1045, 1004, 990, 943, 862, 733; MS (EI): m/z: 111 (23), 93 (84), 91 (20), 84 (71), 79 (24), 77 (26), 71 (41), 66 (100), 54 (41), 45 (78); HRMS (EI): m/z: calc. for C₈H₁₄O: 126.1046 [M], found: 126.1045.

(S)-Oct-6-yn-2-yl propiolate (16). Propiolic acid (1.19 g, 16.6 mmol) was dissolved in THF (15 mL) and

the solution cooled to 0°C before diisopropyl azodicarboxylate (2.42 mL, 2.46 g, 12.2 mmol) was added. Next, a solution of alcohol **S2** (1.40 g, 11.1 mmol) and PPh₃ (3.79 g, 14.4 mmol) in THF (15 mL) was introduced over the course of 1 h.

The resulting mixture was allowed to warm to room temperature and stirring was continued for 16 h. tert-Butyl methyl ether (100 mL) was added and the obtained red solution was washed with H_2O_2 (10 wt-% in water, 3 x 30 mL) and sat. aq. NaHCO₃ (50 mL). The organic phase was dried over Na_2SO_4 , filtered and concentrated to ca. 10 mL (250 mbar). This residue was subjected to flash chromatography (SiO₂, hexane/tert-butyl methyl ether, 30/1) to give the title compound as pale yellow oil (1.30 g, 66%). $\left[\alpha\right]_D^{20} = +28.8$ (c = 1.2, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ = 5.04 (dqd, J = 7.5, 6.2, 5.1 Hz, 1H), 2.85 (s, 1H), 2.15 (tq, J_1 = 7.0, 2.6 Hz, 2H), 1.77 (t, J = 2.6 Hz, 3H), 1.75-1.47 (m, 4H), 1.29 (d, J = 6.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 152.5, 78.6, 76.3, 75.2, 74.3, 73.6, 35.0, 24.9, 19.9, 18.7, 3.6; IR (film) \tilde{v} = 3264, 2981, 2939, 2865, 2115, 1453, 1381, 1231, 1130, 1080, 755; MS (EI): m/z: 163 (0.4), 135 (3), 121 (5), 108 (12), 93 (95), 79 (25), 66 (100), 53 (86); HRMS (ESI): m/z: calc. for $C_{11}H_{14}O_2Na$: 201.0887 [M+Na]⁺, found: 201.0886.


Preparation of (R)-bis(3,5-di-tert-Butylphenyl)(1-methylpyrrolidin-2-yl)methanol (25). This ligand

Once the addition was complete, the mixture was stirred at 80 °C for 2 h. The resulting solution was slowly added to a solution of benzyl 2-methyl (*R*-pyrrolidine)-1,2-dicarboxylate (N-Cbz D-proline methyl ester, 1.79 g, 6.80 mmol) in THF (7.4 mL) at 0 °C. The mixture was warmed to room

temperature and stirred for 2 h. The reaction was carefully quenched with sat. aq. NH_4CI (10 mL) and extracted with *tert*-butyl methyl ether (3 x 100 mL). The combined organic phases were washed with sat. aq. $NaHCO_3$ (30 mL) and brine (30 mL) before they were dried over Na_2SO_4 , filtered and concentrated. The residue was purified by flash chromatography (SiO_2 , hexane/EtOAc, 9/1) to give a mixture of the target compound **25** and di-*tert*-butylbenzene.

This mixture was dissolved in THF (90 mL) and cooled to 0 °C before LiAlH₄ (684 mg, 18.0 mmol) was added portionwise over a period of 5 min. The cooling bath was removed and the mixture stirred at 90 °C for 30 min. The reaction was carefully quenched at 0°C with sat. aq. NH₄Cl (ca. 10 mL). A saturated aqueous solution of Rochelle's salt (5 mL) was added and the mixture was stirred for 45 min. Insoluble material was filtered off through a pad of Celite, the filtrate was checked for a pH > 8 and extracted with tert-butyl methyl ether (3 x 100 mL). The combined organic phases were dried over Na₂SO₄, filtered and concentrated to give a colorless oil containing small amounts of a white solid. This material was dissolved in hexane and kept at 4 °C to allow for crystallization (scratching of the flask with a glass rod was necessary). After 16 h, compound 25 was collected as a white amorphous solid (2.58 g, 77%); after concentration of the mother liquor and repeated crystallization, a second crop of product was obtained (380 mg, 11%). m.p. = 138-142 °C (hexane); $\alpha_D^{20} = -13.7$ (c = 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ = 7.55 (d, J = 1.8 Hz, 2H), 7.41 (d, J = 1.8 Hz, 2H), 7.16 (d, J = 2.8, 1.8 Hz, 2H), 4.65 (s, 1H), 3.58 (dd, J = 9.5, 4.9 Hz, 1H), 3.08 (dd, J = 9.5, 7.4 Hz, 1H), 2.45-2.39 (m, 1H), 1.82-1.77 (m, 1H), 1.73 (s, 3H), 1.71-1.57 (m, 3H), 1.30 (s, 18H), 1.29 (s, 18H); ¹³C NMR (100 MHz, $CDCl_3$): $\delta = 149.9$, 149.8, 147.7, 146.2, 120.1, 119.8, 119.7, 119.5, 77.9, 73.2, 59.5, 43.0, 35.1, 35.0, 31.74, 31.72, 30.0, 24.0; IR (film) \tilde{v} = 2962, 2904, 2868, 2787, 1598, 1362, 1214, 742, 668; MS (EI): m/z: 476 (0.3), 407 (0.7), 392 (2), 302 (0.6), 217 (4), 161 (2), 133 (1), 84 (100), 57 (5); HRMS (ESI): m/z: calc. for C₃₄H₅₄NO: 492.4200 [M+H]⁺, found: 492.4200.

(S)-Oct-6-yn-2-yl (S)-4- $\{(1R,2R,4S)$ -4- $\{(tert$ -butyldimethylsilyl)oxy $\}$ -2- $\{(prop-1-yn-1-yl)$ cyclopentyl $\}$ -4-




hydroxybut-2-ynoate (17). ^[9] Compound **25** (101 mg, 0.21 mmol, 27.5 mol-%) was dissolved in dry toluene (600 μL). Ester **16** (207 mg, 1.16 mmol) was added, followed by careful addition of Me₂Zn (1.2 м in toluene, 940 μL, 1.13 mmol) and a solution of aldehyde **13** (200 mg, 0.75 mmol) in toluene (840 μL). The mixture was stirred for 16 h at ambient temperature before the

reaction was carefully quenched with sat. aq. NH_4Cl . The mixture was extracted with EtOAc (3 x 25 mL), the combined organic phases were dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The remaining yellow oil was purified by flash chromatography (SiO_2 , toluene/EtOAc, 50/1) to give the title compound as colorless oil (247 mg, 74%).

The reaction was also performed on larger scale, using aldehyde **13** (1.67 g, 6.28 mmol), ester **16** (1.73 g, 9.73 mmol), dimethylzinc (1.2 M in toluene, 7.85 mL, 9.42 mmol), **25** (772 mg, 1.57 mmol, 25 mol-%) and toluene (12 mL) to give the title compound (1.84 g, 66%), which analyzed as follows: $\left[\alpha\right]_D^{20} = -12.3$ (c = 1.0, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ = 5.02 (ddq, J = 7.6, 6.2, 5.1 Hz, 1H), 4.68 (dd, J = 7.0, 3.3 Hz, 1H), 4.23 (p, J = 5.8 Hz, 1H), 2.63-2.46 (m, 2H), 2.39 (d, J = 7.0 Hz, 1H), 2.31 (ddd, J

= 13.4, 7.5, 6.1 Hz, 1H), 2.17-2.12 (m, 2H), 1.78-1.77 (m, 6H), 1.75-1.40 (m, 7H), 1.28 (d, J = 6.2 Hz, 3H), 0.88 (s, 9H), 0.04 (s, 6H); ¹³C NMR (100 MHz, CDCl₃): δ = 153.1, 86.3, 81.1, 78.6, 77.7, 77.4, 76.2, 73.3, 71.8, 63.6, 49.8, 43.8, 36.6, 35.0, 30.0, 26.0, 24.9, 20.0, 18.7, 18.2, 3.7, 3.6, -4.61, -4.63; IR (film) \tilde{v} = 3461br, 2929, 2856, 2233, 1709, 1462, 1378, 1360, 1252, 1112, 1051, 836, 775; MS (EI): m/z: 401 (5), 387 (30), 279 (39), 209 (12), 187 (14), 169 (11), 161 (11), 159 (13), 141 (12), 131 (17), 115 (11), 109 (93), 105 (19), 91 (20), 75 (100), 67 (42); HRMS (ESI): m/z: calc. for $C_{26}H_{40}O_4SiNa$: 467.2597 [M+Na]⁺, found: 467.2588.


(S)-Oct-6-yn-2-yl (R,E)-4- $\{(1R,2R,4S)$ -4- $\{(tert$ -butyldimethylsilyl)oxy]-2- $\{(prop-1-yn-1-yl)\}$ -2- $\{(tert)$ -butyldimethylsilyl)oxy]-2- $\{(tert)$ -butyldimethylsilyl)oxy]-2- $\{(tert)\}$ -butyldimethylsilyl)oxy]-2-(tert)-butyldimethylsilylioxy]-2-(tert)-butyldimethylsil



4-hydroxybut-2-enoate (S3). Red-Al (65 wt-% in toluene, 3.03 mL, 10.1 mmol) was added dropwise at -78 °C to a solution of compound **17** (2.25 g, 5.05 mmol) in THF (76 mL) and the resulting mixture was stirred at this temperature for 20 min. Sat. aq. NH₄Cl was then used to quench the reaction. The resulting mixture was allowed to warm to room temperature

before it was extracted with EtOAc [4 x 50 mL, in order to facilitate extraction, saturated aq. Rochelle's salt solution (15 mL) was added]. The combined organic phases were dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography (SiO₂, hexane/EtOAc , 12/1) to give the title compound as pale yellow oil (2.10 g, 93%). $\left[\alpha\right]_D^{20} = -9.5$ (c = 1.0, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃): δ = 6.98 (dd, J = 4.5, 15.6 Hz, 1H), 6.06 (dd, J = 1.8, 15.6 Hz, 1H), 4.99 (sext., J = 6.3 Hz, 1H), 4.52-4.48 (m, 1H), 4.21-4.15 (m, 1H), 2.51-2.43 (m, 1H), 2.38-2.24 (m, 2H), 2.14 (tq, J = 7.0, 2.5 Hz, 2H), 1.79-1.77 (m, 6H), 1.73-1.46 (m, 7H), 1.26 (d, J = 6.2 Hz, 3H), 0.87 (s, 9H), 0.03 (s, 3H), 0.02 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 166.2, 149.1, 121.2, 81.3, 78.8, 76.9, 76.1, 72.0, 71.1, 70.9, 49.8, 43.7, 35.3, 35.2, 30.6, 26.0, 25.1, 20.2, 18.8, 18.2, 3.7, 3.6, -4.60, -4.61; IR (film) \tilde{v} = 3472br, 2952, 2929, 2857, 1716, 1699, 1462, 1360, 1254, 1172, 1114, 1084, 1051, 903, 835, 774; MS (EI): m/z: 403 (8), 389 (50), 347 (15), 281 (18), 189 (18), 169 (15), 129 (17), 109 (75), 75 (100), 67 (46); HRMS (ESI): m/z: calc. for C₂₆H₄₂O₄SiNa: 469.2745 [M+Na]⁺, found: 469.2745.

(S)-Oct-6-yn-2-yl (R,E)-4-[(tert-butyldimethylsilyl)oxy]-4-{(1R,2R,4S)-4-[(tert-butyldimethylsilyl)oxy]-2-(prop-1-yn-1-yl)cyclopentyl}but-2-enoate (18). Pyridine (614 μL, 600 mg, 7.59 mmol) and TBSOTf



(871 μ L, 1.00 g, 3.79 mmol) were added at 0 °C to a solution of compound **S3** (1.13 g, 2.53 mmol) in CH₂Cl₂, and the resulting mixture was stirred at this temperature for 30 min. The reaction was quenched with sat. aq. NaHCO₃ and the mixture extracted with EtOAc (3 x 20 mL). The combined organic phases were washed with aq. CuSO₄ (1 M, 5 x 10 mL) and brine (10 mL), dried

over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography (neutral Al₂O₃, hexane/EtOAc, 20/1) to give the title compound as colorless oil (1.32 g, 93%). $\left[\alpha\right]_D^{20} = -16.4$ (c = 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ = 6.89 (dd, J = 4.8, 15.6 Hz, 1H), 5.93 (dd, J = 1.7, 15.6 Hz, 1H), 4.98 (dq, J = 12.4, 6.2 Hz, 1H), 4.48-4.46 (m, 1H), 4.16-4.10 (m, 1H), 2.43-2.34 (m, 1H), 2.27-2.11 (m, 4H), 1.79-1.77 (m, 6H), 1.75-1.58 (m, 4H), 1.54-1.39 (m, 3H), 1.26 (d, J = 6.2 Hz, 3H), 0.92 (s, 9H), 0.86 (s, 9H), 0.08 (s, 3H), 0.02 (s, 3H), 0.02 (s, 3H), 0.01 (s, 3H); ¹³C

NMR (100 MHz, CDCl₃): δ = 166.3, 150.6, 120.6, 81.4, 78.8, 76.4, 76.0, 72.2, 70.74, 70.72, 50.5, 43.7, 35.3, 34.3, 30.7, 26.04, 26.02, 25.1, 20.2, 18.8, 18.31, 18.27, 3.7, 3.6, -4.1, -4.6, -5.0; IR (film) \tilde{v} = 2954, 2930, 2898, 2857, 1719, 1658, 1472, 1463, 1361, 1256, 1170, 1129, 712, 776; MS (EI): m/z: 503 (83), 395 (18), 371 (23), 295 (9), 263 (33), 245 (13), 197 (10), 171 (19), 109 (64), 75 (75), 73 (100), 67 (33); HRMS (ESI): m/z: calc. for $C_{32}H_{56}O_4Si_2Na$: 583.3611 [M+Na]⁺, found: 583.3609.

Cycloalkyne 19. A flame-dried round bottom flask, equipped with a reflux condenser, was charged

TBSO

with molecular sieves [5Å, 3.75 g, powder (dried prior to use at 150 °C under high vacuum)]. A solution of diyne **18** (1.25 g, 2.23 mmol) in dry toluene (560 mL) was added and the slurry was stirred for 30 min before it was heated to 80 °C (oil bath temperature). The reaction was initiated by the addition of a

solution of complex **26** (123 mg, 118 μmol, 5 mol-%) in toluene (5 mL). After stirring for 45 min the mixture was diluted with EtOAc (60 mL) and filtered through a pad of neutral Al₂O₃ which was rinsed with EtOAc (70 mL). The combined filtrates were concentrated under reduced pressure and the residue purified by flash chromatography (neutral Al₂O₃, hexane/EtOAc, 80/1) to give the title compound as colorless oil (752 mg, 67%). $\left[\alpha\right]_D^{20} = -28.6$ (c = 1.1, CHCl₃); ¹H NMR (400 MHz, CDCl₃): δ = 7.59 (dd, J = 2.9, 15.4 Hz, 1H), 5.95 (dd, J = 1.9, 15.4 Hz, 1H), 5.02-4.93 (m, 1H), 4.21-4.14 (m, 1H), 3.96 (ddd, J = 1.9, 3.0, 9.4 Hz, 1H), 2.35-2.14 (m, 4H), 2.01-1.88 (m, 2H), 1.79-1.60 (m, 4H), 1.56-1.38 (m, 2H), 1.28 (d, J = 6.4 Hz, 3H), 0.93 (s, 9H), 0.87 (s, 9H), 0.05 (s, 3H), 0.03 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ = 166.6, 152.4, 118.5, 82.9, 81.9, 76.1, 71.8, 71.0, 53.9, 44.3, 41.9, 36.0, 31.5, 29.9, 26.0, 24.8, 21.1, 19.4, 18.3, 18.2, -4.0, -4.6, -4.7; IR (film) \tilde{v} = 2954, 2929, 2856, 1717, 1463, 1362, 1255, 837, 775; MS (EI): m/z: 449 (84), 373 (6), 317 (16), 289 (7), 251 (100), 197 (8), 73 (64); HRMS (ESI): m/z: calc. for C₂₈H₅₀O₄Si₂Na: 529.3142 [M+Na]⁺, found: 529.3140.

Compound 20. HCl (2 M, 1 mL) was added to a solution of compound 19 (75 mg, 0.15 mmol) in THF

(5.5 mL) and water (5.5 mL). The mixture was stirred for 39 h before the reaction was quenched with sat. aq. $NaHCO_3$ (ca. 4 mL) and extracted with *tert*-butyl methyl ether (3 x 25 mL). The combined organic phases were dried over Na_2SO_4 , filtered and concentrated and the residue was purified by flash chromatography

(SiO₂, hexane/EtOAc, 1/2) to give the title compound as a white solid (38 mg, 92%). m.p. = 189-191 °C (CDCl₃); $\left[\alpha\right]_D^{20} = -13.7$ (c = 0.66, acetone); ¹H NMR (400 MHz, CD₃OD): δ = 7.76 (dd, J = 15.5, 2.8 Hz, 1H), 5.90 (dd, J = 15.5, 2.0 Hz, 1H), 4.94-4.83 (m, 1H), 4.23-4.18 (m, 1H), 4.01 (dt, J = 9.4, 2.3 Hz, 1H), 2.47 (dddt, J = 11.2, 9.0, 5.0, 3.1 Hz, 1H), 2.38 (dd, J = 13.1, 8.6 Hz, 1H), 2.30-2.23 (m, 1H), 2.10-2.00 (m, 2H), 1.97-1.89 (m, 1H), 1.83-1.70 (m, 3H), 1.69-1.59 (m, 2H), 1.26 (d, J = 6.3 Hz, 3H), 1.18-1.10 (m, 1H); ¹³C NMR (100 MHz, CD₃OD): δ = 168.4, 155.0, 118.0, 83.8, 82.8, 76.1, 72.7, 72.0, 54.5, 44.4, 41.6, 36.9, 32.7, 25.9, 21.1, 19.9; IR (film) \tilde{v} = 3364 (br), 3278 (br), 2970, 2948, 2926, 2865, 1711, 1438, 1258, 1111, 1064, 987; MS (ESI): m/z: 301 [M+Na]⁺; HRMS (ESI): m/z: calc. for C₁₆H₂₂O₄Na: 301.1410 [M+Na]⁺, found: 301.1411. Crystals suitable for X-ray diffraction were obtained by slow evaporation of the solvent from a solution of the compound in MeOH/acetone.

Compound 21. In a flame dried Schlenk tube [Cp*Ru(MeCN)₃]PF₆ (57 mg, 0.11 mmol, 5 mol-%) was

dissolved in CH_2Cl_2 (15 mL). A solution of cycloalkyne **19** (1.15 g, 2.27 mmol) in CH_2Cl_2 (5 mL) was added with stirring before this mixture was transferred under Ar via cannula into a pre-dried autoclave. The Schlenk tube was rinsed with additional CH_2Cl_2 (8 mL), which was also added. The autoclave was

pressurized with H₂ (30 bar). After stirring for 4 h, the autoclave was vented and the remaining yellow solution filtered through a pad of neutral Al₂O₃ which was carefully rinsed with EtOAc (50 mL). The combined filtrates were concentrated and the remaining pale brown oil was subjected to flash chromatography (neutral Al₂O₃, hexane/EtOAc, 90/1) to give a mixture of 21 and isomers (981 mg, 85%) (as well as a small amount of overreduced product). This material was purified by preparative HPLC (Nucleodur C18 HTec, 10 μm, 250 x 40, eluent MeOH/H₂O 95/5, 75 mL/min) to give pure 21 as a colorless oil (642 mg, 56%). $\left[\alpha\right]_D^{20} = +20.1$ [c = 0.9, CHCl₃, lit.: $\left[\alpha\right]_D^{23} = +22$ (c 0.72, CHCl₃)]; 1 H NMR (300 MHz, CDCl₃): δ = 7.28 (dd, J = 3.2, 15.5 Hz, 1H), 5.87 (dd, J = 1.8, 15.5 Hz, 1H), 5.62 (ddd, J = 4.5, 10.1, 14.9 Hz, 1H), 5.26 (dd, J = 9.5, 15.2 Hz, 1H), 4.89 (ddq, J = 1.8, 6.3, 10.9 Hz, 1H), 4.22-4.16 (m, 1H), 4.01 (ddd, J = 1.7, 3.0, 9.2 Hz, 1H), 2.30-2.17 (m, 1H), 2.09-1.93 (m, 4H), 1.87-1.64 (m, 3H), 1.59-1.42 (m, 3H), 1.25 (d, J = 6.2 Hz, 3H), 1.00-0.93 (m, 1H), 0.93 (s, 9H), 0.88 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H), 0.03 (s, 3H), 0.02 (s, 3H); 13 C NMR (75 MHz, CDCl₃): δ = 166.6, 152.6, 137.5, 129.5, 118.3, 76.6, 73.0, 71.5, 53.0, 44.0, 43.9, 42.3, 34.3, 32.0, 26.9, 26.0, 21.1, 18.3, 18.2, -3.9, -4.57, -4.60, -4.7; IR (film) \tilde{v} = 2954, 2930, 2857, 1716, 1472, 1462, 1361, 1254, 1122, 1078, 837, 775; MS (EI): m/z: 508 (3), 493 (2), 451 (100), 433 (18), 361 (24), 343 (13), 319 (33), 301 (18), 291 (12), 227 (13), 199 (26), 185 (11), 147 (12), 129 (11), 73 (62); HRMS (ESI): m/z: calc. for C₂₈H₅₂O₄Si₂Na: 531.3297 [M+Na]⁺, found: 531.3296.

(+)-Brefeldin A (1).[11] HCl (2 M in water, 8.2 mL) was added to a solution of compound 21 (632 mg,

1.24 mmol) in THF (46 mL) and water (46 mL) and the resulting mixture was stirred for 39 h at ambient temperature. The reaction was quenched by the addition of aq. sat. NaHCO₃ and the aqueous layer extracted with *tert*-butyl methyl ether (3 x 50 mL). The combined extracts were dried over Na₂SO₄,

filtered and concentrated and the residue was purified by flash chromatography (SiO₂, hexane/EtOAc, 1/2) to give (+)-brefeldin A as a white solid (327 mg, 94%). m.p. = 202-204 °C (MeOH, lit.:^[12] 202-203 °C); ¹H NMR (400 MHz, CD₃OD): δ = 7.46 (dd, J = 15.6, 3.0 Hz, 1H), 5.82 (dd, J = 15.7, 2.0 Hz, 1H), 5.75 (ddd, J = 4.6, 10.5, 15.0 Hz, 1H), 5.28 (dd, J = 9.6, 15.1 Hz, 1H), 4.80 (ddq, J = 1.8, 6.3, 11.0 Hz, 1H), 4.24-4.19 (m, 1H), 4.04 (ddd, J = 2.0, 3.1, 9.5 Hz, 1H), 2.39 (quint, J = 8.5 Hz, 1H), 2.13 (ddd, J = 5.3, 8.8, 13.2 Hz, 1H), 2.05-1.98 (m, 2H), 1.89-1.73 (m, 5H), 1.62-1.54 (m, 1H), 1.45 (dddd, J = 1.3, 5.4, 8.0, 13.3 Hz, 1H), 1.24 (d, J = 6.2 Hz, 3H), 0.94 – 0.85 (m, 1H); ¹³C NMR (100 MHz, CD₃OD): δ = 168.3, 155.1, 138.1, 131.4, 117.7, 76.6, 73.2, 73.0, 53.2, 45.4, 44.1, 41.8, 35.0, 33.0, 28.0, 21.1; IR (film) \tilde{v} = 3352 (br), 3307 (br), 2923, 2893, 2854, 2495, 2455, 1709, 1448, 1255, 1109, 1070, 975; MS (ESI): m/z: 303 [M+Na]⁺; HRMS (ESI): m/z: calc. for C₁₆H₂₄O₄Na: 303.1567 [M+Na]⁺, found: 303.1567. Crystals suitable for X-ray diffraction were obtained by slow evaporation of the solvent from a solution of the compound in MeOH/acetone.

Table S-1. Comparison of ¹H NMR data ([D₄]-MeOH) of (+)-Brefeldin A


ob	served	litero		
δ, ppm	J (Hz)	δ, ppm	J (Hz)	Δδ (ppm)
7.46	15.6, 3.0	7.45	15.6, 3.0	0.01
5.82	15.7, 2.0	5.82	15.7, 2.0	0.00
5.75	4.6, 10.5, 15.0	5.75	4.6, 10.2, 15.0	0.00
5.28	9.6, 15.1	5.27	9.6, 15.1	0.01
4.80	1.8, 6.3, 11.0	4.78	-	0.02
4.24-4.19	-	4.21	-	0.00
4.04	2.0, 3.1, 9.5	4.03	-	0.01
2.39	8.5	2.38	8.7	0.01
2.13	5.3, 8.8, 13.2	2.12	5.4, 8.7, 13.6	0.01
2.05-1.98	-	2.05-1.97	-	0.00
1.89-1.73	-	1.90-1.70	-	0.01
1.62-1.54	-	1.55	-	0.03
1.45	1.3, 5.4, 8.0, 13.3	1.42	-	0.03
1.24	6.2	1.23	6.2	0.01
0.94-0.85	-	0.90	-	0.00


Table S-2. Comparison of ¹³C NMR data ([D₄]-MeOH) of (+)-Brefeldin A


observed	literature ^[12]	
δ, ppm	δ, ppm	Δδ (ppm)
168.3	168.7	-0.4
155.1	155.4	-0.3
138.1	138.4	-0.3
131.4	131.7	-0.3
117.7	118.1	-0.4
76.6	76.9	-0.3
73.2	73.5	-0.3
73.0	73.3	-0.3
53.2	53.5	-0.3
45.4	45.8	-0.4
44.1	44.4	-0.3
41.8	42.1	-0.3
35.0	35.3	-0.3
33.0	33.3	-0.3
28.0	28.3	-0.3
21.1	21.3	-0.2


References


- (a) J. Heppekausen, R. Stade, R. Goddard, A. Fürstner, J. Am. Chem. Soc. 2010, 132, 11045-11057; (b) J. Heppekausen, R. Stade, A. Kondoh, G. Seidel, R. Goddard, A. Fürstner, Chem. Eur. J. 2012, 18, 10281-10299.
- [2] M. D. Mbaye, B. Demerseman, J.-L. Renaud, L. Toupet, C. Bruneau, *Adv. Synth. Catal.* **2004**, *346*, 835-841
- [3] J. E. Ladbury, E. E. Turner, J. Chem. Soc. 1954, 3885-3886.
- [4] (a) H.-J. Gais, T. Lied, Angew. Chem. 1984, 96, 143-145; (b) S. Kobayashi, K. Kamiyama, T. limori, M. Ohno, Tetrahedron Lett. 1984, 25, 2557-2560.
- Y. N. Ito, X. Ariza, A. K. Beck, A. Boháč, C. Ganter, R. E. Gawley, F. N. M. Kühnle, J. Tuleja, Y. M. Wang,
 D. Seebach, Helv. Chim. Acta 1994, 77, 2071-2110.
- [6] H.-J. Gais, K. L. Lukas, W. A. Ball, S. Braun, H. J. Lindner, Liebigs Ann. Chem. 1986, 687-716.
- [7] Compare: Å. Rosenquist, I. Kvarnström, S. C. T. Svensson, B. Classon, B. Samuelsson, *Acta. Chem. Scandinavia* **1992**, *46*, 1127-1129.
- [8] A. M. Gimazetdinov, G. V. Ishmurzina, M. S. Miftakhov, Russ. J. Org. Chem. 2012, 48, 8-17.
- [9] In analogy to: N. Kojima, S. Nishijima, K. Tsuge, T. Tanaka, Org. Biomol. Chem. 2011, 9, 4425-4428.
- [10] Compare: C. T. Meta, K. Koide, *Org. Lett.* **2004**, *6*, 1785-1787.
- [11] Y. Wu, X. Shen, Y.-Q. Yang, Q. Hu, J.-H. Huang, J. Org. Chem. 2004, 69, 3857-3865.
- [12] Y. Wu, X. Shen, Y.-Q. Yang, Q. Hu, J.-H. Huang, Tetrahedron Lett. 2004, 45, 199-202.
- [13] Modified from procedure of: V. Hickmann, A. Kondoh, B. Gabor, M. Alcarazo, A. Fürstner, *J. Am. Chem. Soc.* **2011**, *133*, 13471-13480.
- [14] P. Persich, J. Llaveria, R. Lhermet, T. de Haro, R. Stade, A. Kondoh, A. Fürstner, *Chem. Eur. J.* **2013**, *19*, 13047-13058.
- [15] E. Bartmann, B. Bogdanović, N. Janke, S. Liao, K. Schlichte, B. Spliethoff, J. Treber, U. Westeppe, U. Wilczok, *Chem. Ber.* **1990**, *123*, 1517-1528.
- [16] E. J. Corey, S. Shibata, R. K. Bakshi, *J. Org. Chem.* **1988**, *53*, 2861-2863.


























f1 (ppm)

